MedeliX
Start asking

brinzolamide

Azopt · ATC code S01EC04

Also known as: Brinzolamid · Brand names: Azopt, Aicisi, Brinzo-Vision, Brinzolamid Stada, Azopt %, Brinzopt, Britil

Key facts
Active substance
brinzolamide
ATC code
S01EC04
Authorisation
centrally authorised across the EU (EMA)
Dosage forms
AZOPT 10 mg/ml eye drops, suspension
Marketing authorisation holder
Novartis Europharm Limited
Information as of
2026-10-28

Key facts

Brinzolamide (Azopt) is a sulphonamide carbonic anhydrase inhibitor given as eye drops to lower elevated intraocular pressure.

What it is used for

  • Decrease of elevated intraocular pressure in ocular hypertension.
  • Open-angle glaucoma: as monotherapy in adults unresponsive to beta-blockers or in whom beta-blockers are contraindicated, or as adjunctive therapy to beta-blockers or prostaglandin analogues.

Dosing

  • One drop in the conjunctival sac of the affected eye(s) twice daily; some patients may respond better to one drop three times a day.
  • The dose should not exceed one drop in the affected eye(s) three times daily.
  • Shake the bottle well before use; nasolacrimal occlusion or gently closing the eyelid after instillation reduces systemic absorption.
  • If several eye medicines are used, administer them at least 5 minutes apart; eye ointments last.
  • No dose adjustment in the elderly; not recommended in hepatic impairment or in children and adolescents.

Contraindications

  • Hypersensitivity to the active substance or any excipient.
  • Known hypersensitivity to sulphonamides.
  • Severe renal impairment (creatinine clearance < 30 ml/min).
  • Hyperchloraemic acidosis.

Important warnings

  • Absorbed systemically; sulphonamide-type reactions including Stevens-Johnson syndrome and toxic epidermal necrolysis may occur - withdraw immediately if serious reactions appear.
  • Caution in patients at risk of renal impairment because of possible metabolic acidosis.
  • Concomitant use with oral carbonic anhydrase inhibitors is not recommended.
  • Contains benzalkonium chloride, which can cause keratopathy and discolour soft contact lenses; remove lenses before instillation and wait at least 15 minutes before reinsertion.
  • Careful monitoring in compromised corneas (e.g. diabetes mellitus, corneal dystrophies); not recommended in narrow-angle glaucoma.
  • May impair tasks requiring mental alertness or physical coordination.

Side effects

  • Most frequent: dysgeusia (6.0%, bitter or unusual taste) and temporary blurred vision (5.4%) upon instillation.
  • Common: eye irritation, eye pain, foreign body sensation, ocular hyperaemia.
  • Uncommon include corneal erosion, keratitis, headache, dizziness and bradycardia.

Interactions

  • CYP3A4 inhibitors (e.g. ketoconazole, itraconazole, clotrimazole, ritonavir) are expected to inhibit brinzolamide metabolism; caution advised.
  • Possible additive effects with oral carbonic anhydrase inhibitors; combination not recommended.

Pregnancy and breastfeeding

  • Not recommended during pregnancy or in women of childbearing potential not using contraception.
  • For breast-feeding, see the full text.

Summary of the official product information, written with AI on 2026-10-29. Every number was checked automatically against the original text. Not reviewed by a physician – the full official text is authoritative.

Full official text →

Common questions – ask Medelix

For patients

Package leaflet, verbatim

This product has no separate US patient information.

Authorisation and brand names by country

Medicines with exactly this active-substance composition, as listed in the national registers – alphabetical and without ranking. Whether a product is currently available is not shown here.

EU – centrally authorised (all member states)

  • AzoptNovartis Europharm Limited · EMEA/H/C/000267

Source: European Medicines Agency (EMA), product information

Austria

  • AicisiOmnivision Gmbh · 1 register entry
  • Brinzo-VisionOmnivision Gmbh · 2 register entries
  • Brinzolamid StadaStada Arzneimittel Gmbh · 1 register entry

Source: EMA – Article 57 product data (EU/EEA), as of 2026-10-29

Germany

  • AicisiOmnivision Gmbh · 1 register entry
  • Brinzo-VisionOmnivision Gmbh · 2 register entries
  • Brinzolamid1 A Pharma Gmbh, Micro Labs Gmbh, Ratiopharm Gmbh, Heumann Pharma Gmbh & Co. Generica Kg, Hexal Ag, Aliud Pharma Gmbh · 6 register entries

Source: EMA – Article 57 product data (EU/EEA), as of 2026-10-29

Turkey

  • Azopt %NOVARTİS SAĞLIK GIDA VE TARIM ÜRÜNLERİ SAN. VE TİC. A.Ş. · 1 register entry
  • BrinzoptROMPHARM İLAÇ SAN. VE TİC. LTD. ŞTİ. · 1 register entry
  • BritilWORLD MEDICINE İLAÇ SAN. VE TİC. A.Ş. · 1 register entry

Source: TİTCK – Ruhsatlı Beşeri Tıbbi Ürünler Listesi, as of 2026-10-16

Brand names in 20 more European countries
Bulgaria
Бритил
Czechia
Brinzolamid Olikla, Brinzolamide Stada
Denmark
Brinzolamid Stada, Brinzolamide Hexal, Brinzolamide Sandoz
Estonia
Brinzolamide Elvim, Brinzolamide Hexal, Brinzolamide Sandoz
Finland
Brinzolamide Accord, Brinzolamide Hexal
France
Aicisi, Brinzolamide Arrow, Brinzolamide Biogaran, Brinzolamide Cristers, Brinzolamide Eg, Brinzolamide Gnr, Brinzolamide Sandoz, Brinzolamide Viatris
Greece
Aicisi, Optonium
Iceland
Azopt
Ireland
Brinzolamide Accord Healthcare Ireland, Brinzolamide Rowex, Brinzolamide Sandoz
Italy
Aicisi, Brinzaflux, Brinzolamide Eg, Brinzolamide Mylan, Brinzolamide Sandoz
Latvia
Brinzolamide Elvim, Brinzolamide Hexal, Brinzolamide Sandoz
Liechtenstein
Azopt
Lithuania
Brinzolamide Elvim
Netherlands
Brinzo-Vision, Brinzolamide Pharmathen, Brinzolamide Sandoz, Brinzolamide Teva, Brinzolamide Viatris, Brizadopt, Optilamid
Norway
Azopt, Brinzolamide Hexal
Poland
Optilamid
Portugal
Aicisi, Brinzolamida Accord, Brinzolamida Lusomedicamenta
Slovakia
Brinzolamid Olikla, Brizadopt
Spain
Aicisi, Brinzolamida Stada
Sweden
Brinzolamid Stada, Brinzolamide Accord, Brinzolamide Hexal, Brinzolamide Sandoz

EMA – Article 57 product data (EU/EEA), 2026-10-29

Medelix receives no money from pharmaceutical companies. Brand names are listed alphabetically and without ranking.

Other substances in the same group

Another question about this substance?

Medelix answers clinical questions from guidelines, studies and product information – every claim with its source.

Sources

  1. European Medicines Agency. Azopt – EPAR, Product Information. 2026-10-28. https://www.ema.europa.eu/en/documents/product-information/azopt-epar-product-information_en.pdf
  2. EMA – Article 57 product data (EU/EEA), 2026-10-29. https://www.ema.europa.eu/en/human-regulatory-overview/post-authorisation/data-medicines-iso-idmp-standards-post-authorisation/public-data-article-57-database
  3. EMA – Article 57 product data (EU/EEA), 2026-10-29. https://www.ema.europa.eu/en/human-regulatory-overview/post-authorisation/data-medicines-iso-idmp-standards-post-authorisation/public-data-article-57-database
  4. TİTCK – Ruhsatlı Beşeri Tıbbi Ürünler Listesi, 2026-10-16. https://www.titck.gov.tr/dinamikmodul/85

Editorial: Medelix editorial team · last updated 2026-10-28 · How these pages are made · Report an error

Source: European Medicines Agency (EMA), product information. Not advertising, not a treatment recommendation. For questions about your own treatment, ask your doctor or pharmacist.